WuXi Biologics is trading 5.39% higher at HK$50.80, with the move most likely reflecting broader biotech-sector momentum rather than a confirmed company-specific catalyst.
- Biotech was up 2.09%; sector sentiment was supported by Merck KGaA’s reported acquisition of Silence Therapeutics for about $1.3 billion.
- No clear company-specific announcement explaining the October 20 move surfaced in the search.
- A recent company update about its Basel event does not establish a direct catalyst.